Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Target Price at $4.25

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) have been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $4.25.

Several analysts have recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Mersana Therapeutics in a research note on Monday, March 3rd. William Blair initiated coverage on Mersana Therapeutics in a research note on Thursday, February 6th. They issued an “outperform” rating on the stock.

Institutional Trading of Mersana Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of MRSN. US Bancorp DE acquired a new stake in shares of Mersana Therapeutics during the third quarter worth about $31,000. Los Angeles Capital Management LLC increased its position in shares of Mersana Therapeutics by 8.1% during the third quarter. Los Angeles Capital Management LLC now owns 189,660 shares of the company’s stock worth $358,000 after purchasing an additional 14,240 shares in the last quarter. GSA Capital Partners LLP increased its position in shares of Mersana Therapeutics by 368.9% during the third quarter. GSA Capital Partners LLP now owns 271,774 shares of the company’s stock worth $514,000 after purchasing an additional 213,814 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Mersana Therapeutics during the third quarter worth about $52,000. Finally, HealthInvest Partners AB increased its position in shares of Mersana Therapeutics by 191.3% during the third quarter. HealthInvest Partners AB now owns 538,621 shares of the company’s stock worth $1,018,000 after purchasing an additional 353,721 shares in the last quarter. 93.92% of the stock is currently owned by institutional investors and hedge funds.

Mersana Therapeutics Stock Up 3.7 %

Shares of NASDAQ MRSN opened at $0.46 on Thursday. The stock has a market cap of $57.94 million, a P/E ratio of -0.76 and a beta of 1.67. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics has a 12-month low of $0.45 and a 12-month high of $5.11. The business’s fifty day simple moving average is $0.64 and its 200-day simple moving average is $1.50.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The business had revenue of $16.36 million for the quarter, compared to analysts’ expectations of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. As a group, equities analysts predict that Mersana Therapeutics will post -0.62 EPS for the current fiscal year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.